Cancer drug heart risk under the microscope
NCT ID NCT06332131
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study watches 25 people with breast or lung cancer who are getting immune checkpoint inhibitor therapy. Researchers use heart scans and blood tests to see if the treatment harms the heart's tiny blood vessels. No new drugs are given; the goal is to learn how to better protect patients' hearts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors understand how to monitor and protect heart health in cancer patients receiving immune therapy.
- What could go wrong
- This is a small observational study with only 25 participants, so results may not apply to everyone. It does not test any new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?